|
Published by: RRY Publications
Published: Mar. 1, 2007 - 350 Pages
Table of Contents
- Introduction and Overview
- Stem Cell Therapies as Disruptive Technologies
- Stem Cells as In Vivo Drug Stores
- Stem Cell Plasticity
- Stem Cell Safety
- The History of Stem Cells as a Therapy
- Trauma and Fracture
- Trauma and Fracture Care
- Types of Fractures
- The Gustillo-Anderson Classification of Open Injuries
- Causes of Fractures
- High-Energy Injuries
- Low-Energy Injuries
- Stress Fractures
- The Biology of Fracture Healing
- Stem Cell and Other Biologic Treatment of Fractures
- Incidence of Fractures in the United States
- Conventional Treatment of Fractures
- Bone Graft Materials in Fresh Fracture Repair
- Fresh Fracture Market Size
- Average Selling Prices
- Risks Associated With Fracture Repair
- Cranial Maxillofacial
- Maxillofacial Trauma
- Causes of Maxillofacial Trauma
- Common Fractures of Facial Bones
- Nasoethmoid Orbital Fractures
- Zygomatic Fractures
- Mandibular Fractures
- Symptoms
- Internal Orbital Fractures
- Maxillary Fractures
- Symptoms
- Soft Tissue Deformities
- Stem Cell Approach for Treatment of Cranial Maxillofacial Fractures
- Conventional Treatment for Common Types of Facial Fractures
- Nasoethmoid Orbital Fractures
- Zygomatic Fractures
- Mandibular Fractures
- Internal Orbital Fractures
- Maxillary Fractures
- Soft Tissue Deformities
- Craniofacial Surgery
- Cranial Vault (Skull) Surgery
- Facial Bone Surgery
- Orbital Surgery
- Average Selling Prices for CMF Biomaterials
- Stem Cell CMF Market Size
- Cartilage Repair
- The Biology of Cartilage
- Hyaline Cartilage
- Elastic Cartilage
- Fibrous Cartilage
- Causes of Cartilage Injury
- Cellular Approaches to Cartilage Repair
- Mesenchymal Stem Cells (MSCs) for Cartilage and Soft Tissue Repair
- Scaffolds
- Conventional Treatment for Cartilage Repair
- Arthroscopic Chondroplasty (debridement)
- Microfracture
- Implant and Transplant Therapies
- Autologous Chondrocyte Implant (ACI)
- Eligibility
- Complications of ACI Procedure
- Results
- Next-Generation ACI Procedures
- Soft Tissue Grafts
- Mosaicplasty and Osteochondral Autograft Transfer Systems (OATS)
- Ostechondral Allograft Transfer Systems
- Large Joint Reconstruction
- Reasons for Knee or Hip Replacement
- The Impact of Cellular Therapies on Large Joint Reconstruction
- Knee Replacement Surgery
- Types of Knee Implant Fixation
- Risks of the Surgery
- Hip Replacement Surgery
- Cemented procedure
- Non-cemented procedure
- Risks of the Surgery
- Large Joint Revision
- Large Joint Revision Surgery
- Knee Revision Surgery
- Reasons for Knee Revision Surgery
- Procedure
- Risks
- Alternative Surgical Procedures
- Hip Revision Surgery
- Reasons for Hip Revision Surgery
- Procedure
- Risks
- Cardiovascular Disease
- Basics of Cardiovascular Disease
- Cardiovascular Disease—the Most Common Cause of Death Globally
- Risk Factors for Cardiovascular Disease
- Types of Cardiovascular Disease
- Coronary Heart Disease
- Stroke
- Types of Stroke
- Cardiomyopathy
- Valvular Heart Disease
- Pericardial Disease
- Congenital Heart Disease
- Congestive Heart Failure
- Rheumatic Heart Disease
- Stem Cell Treatment of Cardiovascular Disease
- Animal Studies
- Successful Clinical Results
- Traditional Treatment of Coronary Heart Disease
- Coronary Angioplasty or Balloon Angioplasty
- Coronary Artery Bypass Graft (CABG)
- Atherectomy
- Laser Angioplasty
- Treatment of Stroke
- Carotid Endarterectomy
- Cerebral Angioplasty
- Tissue Plasminogen Activator (tPA)
- Nerve Regeneration
- The Human Nervous System
- Peripheral Nervous System
- Types of Nerve Injuries
- Neuropraxia
- Axonotmesis
- Neurotmesis
- Traumatic Injury
- Non-Traumatic Injury
- Nerve Regeneration and Recovery
- Stem Cell Approach for Nerve Regeneration
- Surgical Procedures for Nerve Injuries
- Neurorrhaphy/Nerve Repair
- Nerve Graft
- Carpal Tunnel Syndrome
- Open Release Surgery
- Endoscopic Surgery
- Anti-Inflammation
- Mechanism of Action of Stem Cells in Mediating Inflammation in Humans
- Graft vs Host Disease
- Crohn’s Disease
- Stem Cells for Inflammatory Disease
- Beyond GVHD and Crohn’s Disease
- Diabetes
- The Basics of Diabetes
- Diabetes—A Leading Cause of Death Worldwide
- Stem Cell Approach
- Challenges Faced by the Stem Cell Approach
- Diabetes Management—The Conventional Approach
- Company Profiles
- DM Inc
- Aastrom Biosciences, Inc
- Advanced Cell Technology, Inc
- Aegera Therapeutics Inc
- Aldagen, Inc
- AllCells LLC
- Amersham Biosciences
- Amgen
- Angel Biotechnology
- Applied Tissue Technologies LLC
- Arteriocyte, Inc
- Athersys, Inc
- BeFutur Biotechnologies SA
- Berlex, Inc
- BioE, Inc
- BioHeart, Inc
- Cambrex Corporation
- Cell Dynamics, LLC
- Cell Genesys, Inc
- Cellartis AB
- Cellerant Therapeutics, Inc
- Cellerix SL
- CellGenix Technologie Transfer GmbH
- CellResearch Corp Pte Ltd
- CellTran Limited
- Cellular Dynamics International Inc
- Ceregene Inc
- Chemokine Therapeutics Corp
- Cognate BioServices, Inc
- CorCell
- Covance Inc
- Cytomatrix LLC
- Cytori Therapeutics, Inc
- EmCell
- ES Cell International PTE Ltd
- Gamida Cell Ltd
- Geron Corporation
- Histostem Co Ltd
- Incxyte Corporation
- Intercytex Group plc
- Ixion Biotechnology, Inc
- Kaleidos Pharma, Inc
- Living Cell Technologies Ltd
- MD Biosciences Inc
- Mesoblast Limited
- MG Biotherapeutics, LLC
- Moraga Biotechnology
- NeoStem, Inc
- NeuralStem Biopharmaceuticals, Ltd
- NeuroNova AB
- Neuronyx, Inc
- Novartis AG
- Novocell, Inc
- NsGene A/S
- Odontis Ltd
- Oligene GmbH
- Ortec International, Inc
- PharmaStem Therapeutics, Inc
- Pluristem Life Systems, Inc
- Progenitor Cell Therapy, LLC
- Proneuron Biotechnologies Inc
- Quintiles Transnational Corp
- RegeneRx Biopharmaceuticals, Inc
- Regenetech, Inc
- Regenics A/S
- ReneMed Biologics, Inc
- ReNeuron Group PLC
- Reproductive Genetics Institute
- Saneron CCEL Therapeutics, Inc
- (Bayer) Schering Pharma AG
- Serologicals Corporation (acquired by Millipore)
- SinoCells BioTechnologies Co, Ltd
- Stem Cell Sciences PLC
- Stem Cell Therapeutics Corp
- Stem Cells, Inc
- StemCyte, Inc
- StemCell Technologies Inc
- StemPath Inc
- Stemride International, Ltd
- Tengion, Inc
- TheraVitae Co, Ltd
- Titan Pharmaceuticals, Inc
- Transition Therapeutics Inc
- TriStem Corporation
- US Biodefense, Inc
- Vesta Therapeutics, Inc
- ViaCell, Inc
- VistaGen Therapeutics Inc
- APPENDIX
AbstractSales of stem cell products in the United States reached $16.4 million in 2006 and are expected to surpass $35 million in 2007, according to author Robin R. Young, a medical industry analyst who has been named one of The Wall Street Journal’s “Best on the Street” and among the top 10 analysts in the United States by Institutional Investor. By 2016, companies supplying stem cell products should generate more than $1.2 billion in total revenues and have a combined market value of over $10 billion. Find out about the latest stem cell applications and market trends through the Stem Cell Analysis and Market Forecasts 2006-2016. Over 350 pages of industry-specific research with forecasts and profiles of more than 100 stem cell companies.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.
© MarketResearch.com 2010
|